title: Statin-Associated Muscle Adverse Events: Update for clinicians.
abstract: Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statin-associated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies.
authors.affiliation: Department of Clinical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
authors.forename: Maha A
authors.initials: MA
authors.lastname: Al-Mohaissen
authors.affiliation: Department of Psychiatry, Baystate Medical Center, Tufts University School of Medicine, Springfield, Massachusetts, USA.
authors.forename: Martha J
authors.initials: MJ
authors.lastname: Ignaszewski
authors.affiliation: Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Jiri
authors.initials: J
authors.lastname: Frohlich
authors.affiliation: Department of Cardiology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Ignaszewski
keywords: Adverse Effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Myopathies